Identify novel compounds for FSGS treatment via computational drug screening.
Focal segmental glomerulosclerosis (FSGS) is a glomerular lesion often associated with nephrotic syndrome. There is currently no specific approved therapy for FSGS, and treatment options are limited to systemic administration of corticosteroids, calcineurin inhibitors, and treatment with renin-angiotensin aldosterone system inhibitors. There is a clear medical need for novel treatment options as FSGS patients often progress toward end-stage kidney failure with the need for renal transplantation or dialysis treatment.
Funding agency: WAW (Wiener Wirtschaftsagentur)
Status: Ongoing
Timeline: 2020 – present